From all of us at Rosa & Co, we wish you a wonderful year ahead!
Long before the world knew what to call ‘Quantitative Systems Pharmacology’ (QSP) in the realm of preclinical and clinical drug development, Ron Beaver, Founder, Chairman, and CEO of Rosa & Co. already had his moment of revelation. He realized that deeper understanding of empirical data and effective learning about the connection of drug and disease mechanisms are critical for more informed decisions at all stages in research and development. Driven by his passion for enabling effective experimental and trial design, he founded Rosa in 2002 to deliver an increase in confidence and reduction in risk in pharmaceutical and consumer product research and development. Today, the company holds a unique spot as a global industry-leading pharmacology solution provider for its breadth and depth of understanding of this space.
Read more in Pharma Tech Outlook, Dec 2018: https://www.pharmatechoutlook....
Rosa & Co. LLC, an organization known worldwide for its PhysioPD™ Research Platforms, announced today that it will present two research posters at the 2019 ASCPT Annual Meeting Pre-Conference, “Advancing QSP Toward Predictive Drug Development: From Targets to Treatments,” in Washington, DC, March 13–17, 2019, in collaboration with Sanofi. The posters will address the use of QSP models in metabolic diseases as well as rheumatology research:
1) Incorporation of Renal SGLT Function into a Quantitative Systems Pharmacology (QSP) Model. M. Reed, M. Weis, R. Baillie, H.-C. Schneider, T. Klabunde
2) Evaluation of Novel Anti-TNFα and IL-6R Therapies in a Rheumatoid Arthritis (RA) Quantitative Systems Pharmacology Platform (QSP). V. Hurez, M. Weis, R. Baillie, M. Rehberg, K. Beuke, N. Biesemann, C. Asbrand, T. Klabunde, M. Herrmann, M. Reed
Meet us at the poster sessions on March 13 between 8 a.m.–5 p.m., or contact us to arrange a meeting at another time during the event.
Rosa & Co. LLC, an organization known worldwide for its PhysioPD™ Research Platforms, announced today that it will present posters with Takeda Pharmaceutical Company Ltd, and Boehringer Ingelheim GmbH at the Ninth American Conference on Pharmacometrics (ACoP9) in San Diego, California, October 7–10, 2018. The poster presentations will describe research in a range of therapeutic areas, including immuno-oncology, neurology, and respiratory diseases:
On Monday Oct 8, in the morning, the research poster with Boehringer Ingelheim will be presented: "Development of the Respiratory PhysioPD™ Platform, a Quantitative Systems Pharmacology (QSP) Model, to Investigate Biological Mechanisms Underlying Bronchoconstriction".
On Tuesday, Oct 9, in the morning, Rosa will present: "Evaluation of the Efficacy of a CD122 Biased Agonist for Treatment of Melanoma as a Monotherapy and in Combination with PD-1 Inhibition Using a Mechanistic Physiological Model".
On Wednesday Oct 10, in the afternoon, the poster with Takeda will be presented: "Quantitative Systems Pharmacology Model to Quantify Benefits of DAO Inhibition in Schizophrenia".
“When working with clients, we focus on giving them the tools to test hypotheses to make informed decisions about the disease pathophysiology, mechanism of action of the candidate drugs, and factors responsible for variability in the patient response,” said Rosa Founder, Chairman, and CEO Ron Beaver, PhD. “Using QSP and our PhysioPD™ Research Platform, we surface insights which help biopharma organizations to focus on most promising aspects of the drug efficacy and patient response.”
The posters will be available at www.rosaandco.com/publications after the start of the ACoP9 meeting.
Dr. Katherine Kudrycki, Principal Scientist at Rosa & Co, will present "Evaluation of a novel therapy and identification of uncertainties critical to efficacy and competitive differentiation in a Psoriasis PhysioPD™ Platform. " at the 2018 SID/IID Dermatology meeting in Orlando, FL May 16-19, 2018.
Together with Grünenthal, Rosa & Co developed a Psoriasis QSP model to mechanistically represent the physiology of a single chronic psoriatic plaque (including keratinocytes, immune cells, cytokines and chemokines and their regulation), drug PK and clinical outcomes (e.g., PASI score). At the meeting Dr. Kudrycki will demonstrate how the model was qualified and used to get insights into the therapeutic potential and efficacy of novel small molecule enzyme-specific inhibitors.
For more information, contact Dr. Katherine Kudrycki at firstname.lastname@example.org
We are hiring! Rosa & Co. is looking for a Senior Engineer to work with scientists in our PhysioPD practice to develop mechanistic QSP models and conduct simulations of disease, drug action, and (pre)clinical studies. Download the .pdf for more information: https://www.rosaandco.com/uplo...
The Committee on Credible Practice of Modeling & Simulation in Healthcare invited Rosa’s Chief Engineer, Dr. Christina Friedrich, to present a webinar on how to ensure model quality for Quantitative Systems Pharmacology (QSP) models.
The committee, an initiative started by the Interagency Modeling and Analysis Group and Multiscale Modeling Consortium, aims to establish a task-oriented collaborative platform to outline good practice of simulation-based medicine.
On March 6 Dr. Friedrich's webinar introduced the concept of a Model Qualification Method (MQM) and presented two case studies to illustrate the utility of the method.
The webinar was archived and is freely accessible at https://youtu.be/xk3_8DyoSPQ
Genentech and Rosa will jointly present "Using a Quantitative Systems Pharmacology approach to investigate causes of the adverse GI events associated with prolonged treatment with PI3-Kinase inhibitors" at the 2018 ASCPT Annual meeting in Orlando, FL March 21-24, 2018.
Happy holidays from all of us at Rosa & Co.
Wishing you an amazing 2018!
Engineers work with Scientists in our PhysioPD practice to develop physiologically-based, dynamic mathematical models and conduct simulations of disease, drug action, and (pre)clinical studies.
Rosa & Co., LLC announced today that they will be presenting a record 12 research posters and presentations at the eighth American Conference on Pharmacometrics (ACoP8), to be held in Fort Lauderdale, FL, on October 15–18, 2017.
Rosa & Co announced today that Mike Reed, Chief Scientist at Rosa, will be participating in the panel discussion “QSP in oncology – practical application, challenge and opportunity” at the 32nd Annual meeting of the Japanese Society for the Study of Xenobiotics.
Rosa & Co announced today that Mike Reed, Chief Scientist at Rosa, and Michael Weis, Senior Engineer at Rosa, will present “Diabetes models big and small – case examples from 15 years of scoping, developing, and qualifying fit-for-purpose models for QSP research to support drug development” at the Insulin-Glucose Systems Pharmacology FDA workshop in Washington, DC on August 17-18, 2017.
Rosa & Co today announced that Dr. Meghan Pryor will be participating and presenting at the NIH Quantitative Systems Pharmacology and Neurotherapeutics Drug Discovery Workshop in Bethesda, MD, on July 26 – 27. Dr. Pryor will present a poster entitled “A Quantitative Systems Pharmacology Platform of Brain and Serum Progranulin (PGRN) to Investigate Targets in Frontotemporal Dementia (FTD)”. The poster shows how the PGRN PhysioPD Research Platform has been proven to be useful to simulate the effects of modulating different targets and investigating drug effects on increasing PGRN for the treatment of FTD.
Rosa & Co. LLC is pleased to announce the renewal of a multi-year Research Agreement with Sanofi to provide Rosa’s PhysioPD™ services. The continuing collaboration provides Sanofi with competitive research and development advantage with access to Rosa’s expertise in Quantitative Systems Pharmacology.
Rosa & Co., LLC is proud to welcome Matt Marano as the company's Senior Vice President of Business Development. Mr. Marano will be responsible for leading the continued expansion of the company's worldwide PhysioPD™ commercial strategy. Mr. Marano joins the team from SolveBio (New York, NY) where he served as Senior Vice President of Commercial Development. During his tenure at SolveBio, he directed all sales and business development efforts, specifically focusing on VP- and C-level executives within the Life Sciences industry. Prior to SolveBio, Mr. Marano was Vice President of Sales and Business Development at Gen9 (acquired by Ginkgo Bioworks), a leading next-generation gene synthesis provider, where he successfully led the organization's commercial expansion in the United States, Europe, the Middle East and Africa.
"I am thrilled to be joining the world-class team at Rosa & Co. I've focused much of my career on expanding the commercial presence of some of the Life Science industry's most impactful companies, and Rosa is truly the world leader in Quantitative Systems Pharmacology solutions for the Life Sciences industry," said Matt Marano about his appointment. "We are fortunate that an executive of Matt's stature has joined our team. Together we can further expand our ability to offer PhysioPD Research to clients world-wide," said Founder, Chairman, & CEO Ron Beaver, PhD.
Rosa announces that Mike Reed, Chief Scientist at Rosa will present at the 21st International Congress of Parkinson’s Disease and Movement Disorders meeting on June 7th in Vancouver, BC, Canada. The poster entitled "Application of a Qualitative Model to Elucidate the Role of the Alpha-Synuclein System in Parkinson’s Disease" describes the development of a Synuclein PhysioMap®, a graphical model architecture to support hypothesis generation and testing. The Synuclein PhysioMap enabled identification of key biological uncertainties and hypotheses and the recommendation of focused laboratory experiments to gain a better understanding of synuclein function in Parkinson’s disease.
Rosa announces that it will present two posters at the Society For Investigative Dermatology (SID) Annual Meeting on March 15th in Portland, OR. The first poster entitled " Mechanistic physiological modeling as a tool for enhancing dermatology research" describes the use of PhysioPD™ Platforms in dermatology drug research and development for acne, atopic dermatitis (AD), psoriasis, skin aging, and erythema indications will be presented by Christina Friedrich, Chief Engineer at Rosa & Co. The second poster entitled “Mechanistic modeling facilitates identification of key pathways involved in dermal aging and potential new targets for anti-aging intervention” is a joint presentation between Proctor & Gamble and Rosa & Co and will be presented by Katherine Kudrycki, Principal Scientist at Rosa. The poster describes the development of a Skin PhysioPD™ Research Platform, a quantitative physiological model representing the physiology of aged dermis and the effects of anti-aging treatments and the use of this Platform to research treatments for photoaged skin.
Rosa and Co. LLC, founded in January 2002, is celebrating its 15-year milestone as an employee-owned drug-development advisory firm. As part of it’s anniversary celebration, Rosa has launched a new website (www.rosaandco.com) to better reflect its industry-leading scientific capabilities and support the development of the broader PhysioPD-style modeling community.
Rosa announces that Christina Friedrich, Chief Engineer at Rosa, will present at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting on March 15th in Washington DC. The poster entitled "Model Qualification Approaches For Quantitative Systems Pharmacology and Mechanistic Physiological Models" compares and contrasts newly proposed Quantitative Systems Pharmacology (QSP) qualification approaches with the use of the Model Qualification Method (MQM) in qualifying QSP/PhysioPD™ models.